KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma
Go back to KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma| Merck & Co. (NYSE: MRK) | Delayed: 144.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $144.91 | 52 Week High | $65.46 | |||
| Open | $144.91 | 52 Week Low | $47.97 | |||
| Day High | $144.91 | P/E | 98.58 | |||
| Day Low | $144.91 | EPS | $1.47 | |||
| Volume | 15,906 | |||||
